Elevance Health posts $49.8 billion Q2 revenue

• Elevance Health generated $49.8 billion in second-quarter operating revenue with an adjusted diluted earnings per share of $7.45.
• The company raised its full-year 2026 adjusted diluted earnings per share guidance to at least $27.
• Management stated the firm is accelerating targeted investments to strengthen the integrated healthcare solutions of Carelon.

Elevance Health (NYSE:ELV) reported second-quarter 2026 operating revenue of $49.8 billion and a diluted earnings per share of $6.71.

This operating revenue represents a 0.8% increase from the second quarter of 2025.

The company achieved an adjusted diluted earnings per share of $7.45, supported by favorable benefit expense performance.

Elevance Health noted these results also included an approximately $0.80 per share net below-the-line benefit.

Following the announcement, Elevance Health's share price was up at $439.60.

The firm stated it raised its full-year 2026 diluted earnings per share guidance to at least $20.10.

Elevance Health also increased its operating cash flow forecast to at least $6 billion to support Carelon's integrated solutions.